Guggenheim upgraded Neumora Therapeutics (NMRA) to Buy from Neutral with a $14 price target following the “compelling” preclinical obesity data reported by the company. The firm views the company’s NLRP3i program in obesity and related disorders as “a clear driver to value creation,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics
- Neumora Therapeutics Begins Phase 1 Study for NMRA-898
- Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988
- Neumora Reports Positive Preclinical Results for NMRA-215
- Neumora Therapeutics’ NMRA-215 shows weight loss efficacy